CGON Stock Analysis: CG Oncology, Common stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.109m USD | 12M Return: 163.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.8M
Qual. Beats: -1
Rev. Trend: 99.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 2.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy, for the treatment of bladder cancer in the United States. The company is advancing cretostimogene through an extensive clinical program targeting non-muscle invasive bladder cancer (NMIBC), including Phase 3 trials (BOND-003 Cohort C, BOND-003 Cohort P, and PIVOT-006) in BCG-unresponsive and intermediate-risk settings, as well as Phase 2 trials (CORE-008) in high-risk NMIBC patients. Oncolytic immunotherapy is a class of cancer treatment that uses engineered viruses to selectively infect and destroy tumor cells while stimulating an anti-tumor immune response. The company is classified within the GICS Health Care sector under the Biotechnology sub-industry, completed its IPO on January 25, 2024, and is headquartered in Dallas, Texas. CG Oncology was founded in 2010 and was formerly known as Cold Genesys, Inc. before adopting its current name in June 2020.
- Phase 3 BOND-003 data readout approaches for cretostimogene
- FDA approval pathway advances for bladder cancer therapy
- Competition intensifies from Pfizer Adstiladrin in NMIBC market
| Net Income: -186.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -2.84 > 1.0 |
| NWC/Revenue: 21.0k% < 20% (prev 102k%; Δ -81.5k% < -1%) |
| CFO/TA -0.14 > 3% & CFO -160.0m > Net Income -186.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 31.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.5m) vs 12m ago 10.93% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.54% > 50% (prev 0.09%; Δ 0.45% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 1.10b - Total Current Liabilities 35.2m) / Total Assets 1.14b |
| B: -0.39 (Retained Earnings -439.2m / Total Assets 1.14b) |
| C: -0.20 (EBIT TTM -186.7m / Avg Total Assets 931.7m) |
| D: 25.11 (Book Value of Equity 1.09b / Total Liabilities 43.5m) |
| Altman-Z'' = 29.92 = AAA |
| DSRI: 0.48 (Receivables 1.27m/345k, Revenue 5.07m/662k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.34 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 7.66 (Revenue 5.07m / 662k) |
| TATA: -0.02 (NI -186.7m - CFO -160.0m) / TA 1.14b) |
| Beneish M = 0.93 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 69.20 with a total of 967,607 shares traded. Over the past week, the price has changed by -6.14%, over one month by +27.21%, over three months by -0.87% and over the past year by +163.62%.
Current recommended Stop Loss: 64.60 (which is 6.6% or 1.3 ATR below the current price).
CG Oncology, Common stock has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy CGON.
- StrongBuy: 5
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 90.3 | 30.5% |
P/S = 1204.6743
P/B = 5.6875
Revenue TTM = 5.07m USD
EBIT TTM = -186.7m USD
EBITDA TTM = -184.5m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 1.07m USD (from shortTermDebt, last quarter)
Debt = 12.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.58m
Net Debt = -1.06b USD (calculated: Debt 12.2m - CCE 1.08b)
Enterprise Value = 5.04b USD (6.11b + Debt 12.2m - CCE 1.08b)
Interest Coverage Ratio = unknown (Ebit TTM -186.7m / Interest Expense TTM 0.0)
EV/FCF = -31.44x (Enterprise Value 5.04b / FCF TTM -160.4m)
FCF Yield = -3.18% (FCF TTM -160.4m / Enterprise Value 5.04b)
FCF Margin = -3.16k% (FCF TTM -160.4m / Revenue TTM 5.07m)
Net Margin = -3.68k% (Net Income TTM -186.7m / Revenue TTM 5.07m)
Gross Margin = unknown ((Revenue TTM 5.07m - Cost of Revenue TTM 38.8m) / Revenue TTM)
Tobins Q-Ratio = 4.44 (Enterprise Value 5.04b / Total Assets 1.14b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 12.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -147.5m (EBIT -186.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 31.30 (Total Current Assets 1.10b / Total Current Liabilities 35.2m)
Debt / Equity = 0.01 (Debt 12.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 5.77 (negative EBITDA) (Net Debt -1.06b / EBITDA -184.5m)
Debt / FCF = 6.63 (negative FCF - burning cash) (Net Debt -1.06b / FCF TTM -160.4m)
Total Stockholder Equity = 800.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.04% (Net Income -186.7m / Total Assets 1.14b)
RoE = -23.33% (Net Income TTM -186.7m / Total Stockholder Equity 800.6m)
RoCE = -23.24% (EBIT -186.7m / Capital Employed (Equity 800.6m + L.T.Debt 3.00m))
RoIC = -13.40% (negative operating profit) (NOPAT -147.5m / Invested Capital 1.10b)
WACC = 10.24% (E(6.11b)/V(6.12b) * Re(10.26%) + D(12.2m)/V(6.12b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 11.14%
[DCF] Fair Price = unknown (Cash Flow -160.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.61 | # QB: -1
Revenue Correlation: 99.62 | Revenue CAGR: 345.0% | SUE: 0.83 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=+0.00% | Revisions=-25% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.67 | Chg30d=+0.00% | Revisions=-25% | Analysts=12
EPS current Year (2026-12-31): EPS=-2.66 | Chg30d=+0.00% | Revisions=-46% | GrowthEPS=-27.7% | GrowthRev=+190.4%
EPS next Year (2027-12-31): EPS=-2.78 | Chg30d=+0.00% | Revisions=-77% | GrowthEPS=-4.7% | GrowthRev=+670.5%
[Analyst] Revisions Ratio: -54% (up=8, down=30)